Open AccessComparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
Author(s) -
Deepak Almeida,
Paul J. Converse,
Si-Yang Li,
Anna M. Upton,
Nader Fotouhi,
Eric Nuermberger
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01412-21
Subject(s) - bedaquiline , linezolid , tuberculosis , pharmacology , medicine , regimen , multiple drug resistance , drug resistance , mycobacterium tuberculosis , microbiology and biotechnology , biology , bacteria , genetics , pathology , vancomycin , staphylococcus aureus
Bedaquiline (BDQ, B) is the first-in-class diarylquinoline to be approved for treatment of tuberculosis (TB). Recent guidelines recommend its use in treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).